Page 172 - 2021_07-Haematologica-web

A.S. Zayac et al.
Organization classification of lymphoid
neoplasms. Blood. 2016;127(20):2375-2390. 18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-
586.
19.Fine JP, Gray RJ. A proportional hazards
model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 1999;94(446):496- 509.
20. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-399.
21.Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-ritux- imab is safe and effective for HIV-associat- ed Burkitt lymphoma. Blood. 2015;126(2):160-166.
22. Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lym- phoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870- 3879.
23. Corazzelli G, Frigeri F, Russo F, et al. RD- CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable'
highly aggressive B-cell lymphoma. Br J
Haematol. 2012;156(2):234-244.
24. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophe- notypic criteria (MRC/NCRI LY10 trial).
Blood. 2008;112(6):2248-2260.
25. Wasterlid T, Brown PN, Hagberg O, et al.
Impact of chemotherapy regimen and rit- uximab in adult Burkitt lymphoma: a retro- spective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879-1886.
26. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13(8):1264-1274.
27. Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapt- ed pediatric LMB protocol. Ann Oncol. 2005;16(12):1928-1935.
28.Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multia-
gent chemotherapy tailored to the tumor burden and initial response in 561 unselect- ed children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-3379.
29.Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refrac- tory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114-E117.
30. Decker DP, Egan PC, Zayac AS, Treaba DO, Olszewski AJ. Treatment strategies and risk of central nervous system recur- rence in high-grade B-cell and Burkitt lym- phoma. Leuk Lymphoma. 2020;61(1):198- 201.
31 Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(2):173-179.
32. Gastwirt JP, Roschewski M. Management of adults with Burkitt lymphoma. Clin Adv Hematol Oncol. 2018;16(12):812-822.
33. Dunleavy K. Approach to the diagnosis and treatment of adult Burkitt's lymphoma. J Oncol Pract. 2018;14(11):665-671.
1942
haematologica | 2021; 106(7)